References
- Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plann. 2013;28(7):692–704. DOI:10.1093/heapol/czs108
- Schafheutle EI, Hassell K, Noyce PR. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community. 2002;10(3):187–195.
- Oridanigo EM, Salgedo WB, Kebene FB. Affordability of essential medicines and associated factors in public health facilities of Jimma Zone. Southwest Ethiopia Adv Pharmacol Pharm Sci. 2021;2021:6640133.
- WHO. How to develop and implement a national drug policySecondUpdates and replaces guidelines for developing national drug policies1988 Available athttps://www.who.int/activities/promoting-national-medicines-policiesAccessed Dec 2022
- Hoebert JM, van Dijk L, Mantel-Teeuwisse AK, et al. National medicines policies – a review of the evolution and development processes. J Pharm Policy Pract. 2013;6:5. https://www.joppp.org/content/6/1/5
- Tao W, Agerholm J, Burström B. The impact of reimbursement systems on equity in access and quality of primary care: a systematic literature review. BMC Health Service Res. 2016;16(1):542. DOI:10.1186/s12913-016-1805-8
- Frost LJ, Reich MR ACCESS: how do good health technologies get to poor people in poor countries? Harvard Center for Population and Development Studies, 2008. Available at: https://cdn1.sph.harvard.edu/wp-content/uploads/sites/480/2012/10/accessbook.pdf (Accessed Nov. 2022)
- United nations. Access to medicines and the right to health. Special Rapporteur on the right to health. Available at: https://www.ohchr.org/en/special-procedures/sr-health/access-medicines-and-right-health (Accessed Nov. 2022)
- Sen RJ S.2257 - expanding access to affordable prescription drugs and medical devices act, 117th Congress (2021-2022), Available at: https://www.congress.gov/bill/117th-congress/senate-bill/2257?s=1&r=74 (Accessed Nov. 2022)
- EC. Pharmaceutical strategy for Europe, 2020. Available at: https://health.ec.europa.eu/system/files/2021-02/pharma-strategy_report_en_0.pdf (Accessed Nov 2022).
- Jakubowski E, Busse R Health care systems in the EU. European parliament, directorate general for research1998, https://www.europarl.europa.eu/workingpapers/saco/pdf/101_en.pdf (Accessed Feb. 2023)
- Rietveld Ad H, Haaijer-Ruskamp FM. Policy options for cost containment of pharmaceuticals. Int J Risk Saf Med. 2002;15:29–54.
- World Health Organization. The World drug situation. 1988. Available from: https://apps.who.int/iris/handle/10665/37781 (Accessed Dec 2022).
- McGhan WF, Rowland CR, Bootman JL. Cost-benefit and cost-effectiveness: methodologies for evaluating innovative pharmaceutical services. Am J Hosp Pharm. 1978;35(2):133–140.
- Hopwood DA, Chater KF. Fresh approaches to antibiotic production. Philos Trans R Soc Lond B Biol Sci. 1980;290(1040):313–328.
- Mapes R. Prescribing costs and prescriber accountability. J R Coll Gen Pract. 1976;26(Suppl 1):96–102.
- WHO. Access to medicines and health products. WHO guideline on country pharmaceutical pricing policies. World health organisation. Geneva; 2020. https://www.who.int/publications/i/item/9789240011878
- Heidari E, Varmaghani M, Abdollahiasl A. Availability, pricing and affordability of selected medicines for noncommunicable diseases. EMHJ. 2019;25(7):473–480.
- Kanavos P, Vandoros S, Irwin R, et al. Differences in costs of and access to pharmaceutical product in EU. European parliament 2011, Directorate general for international policies. Available from: https://www.europarl.europa.eu/RegData/etudes/etudes/join/2011/451481/IPOL-ENVI_ET/2011/451481_EN.pdf (Accessed Nov 2022)
- OECD. Pharmaceutical pricing policies in a global market. OECD 2008; ISBN 978-92-64-04414-2 ISBN 978-92-64-04414-2 https://www.oecd.org/els/pharmaceutical-pricing-policies-in-a-global-market.htm
- Verghese N, Barrenetxea J, Bhargava Y, et al. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. J Mark Access Health Policy. 2019;7:1601060. DOI:10.1080/20016689.2019.1601060
- Kanavos P, Fontrier A-M, Gill J, et al. Nicola Boekstein the Impact of external reference pricing within and across countries. Lse. 2017. DOI:10.21953/lse.m0bluqcv10g6
- Marinoso G, Jelovac BI, Olivella P. External Referencing and Pharmaceutical Price Negotiation. Health Econ. 2011;20(6):737–756.
- Holtorf AP, Gialama F, Wijaya KE, et al. External reference pricing for pharmaceuticals—A survey and literature review to describe best practices for countries with expanding healthcare coverage. Value Heal Reg Issues. 2019;19:122–131.
- Kanavos P, Fontrier AM, Gill J, et al. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Heal Econ. 2020;21(1):129–151.
- Yfantopoulos J. Pharmaceutical pricing and reimbursement reforms in Greece. Eur J Health Econ. 2008;9(1):87–9710.
- Rémuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3(1):3. DOI:10.3402/jmahp.v3.27675
- Leopold C, Vogler S, Mantel-Teeuwisse AK, et al. Differences in external price referencing in Europe-A descriptive overview. Health Policy. 2012;104(1):50–60. DOI:10.1016/j.healthpol.2011.09.008
- Kalo Z, Alabbadi I, Al Ahdab OG, et al. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):993–998. DOI:10.1586/14737167.2015.1048227
- https://euripid.eu/ Accessed 30 Nov 2022
- Vogler S, Zimmermann N, De Joncheere K. The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research? J Pharm Policy Pract. 2015:8(Suppl 1):E4. DOI:10.1186/2052-3211-8-S1-E4
- Adriaen M, De Witte K, Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. J Generic Med. 2008;5(3):175–187.
- Maniadakis N, Kourlaba G, Shen J, et al. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. BMC Health Serv Res. 2017;17(1):1–17.
- Hasan SS, Kow CS, Dawoud D, et al.Pharmaceutical policy reforms to regulate drug prices in Asia Pacific Region: the case of AustraliaPharmaceutical policy reforms to regulate drug prices in Asia Pacific Region: the case of AustraliaChina India Malaysia NewValue Heal Reg Issues2019Vol. 18p. 18–23. DOI:10.1016/j.vhri.2018.08.007
- Moorkens E, Vulto A, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12(12):e0190147. DOI:10.1371/journal.pone.0190147
- Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9(20):1070. DOI:10.3389/fphar.2018.01070
- Malinowski P, Kawalec P, Trabka W, et al. Reimbursement legislations and decision making for orphan drugs in Central and Eastern European countries. Front Pharmacol. 2019;10(8):487. DOI:10.3389/fphar.2019.00487
- Leopold C, Rovira J, Habl C. Generics in small markets or for low volume medicines European Union. Vienna: EMINet; 2010.
- Kanavos P, Ferrario A, Vandoros S, et al. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff. 2013;32(4):753–761.
- Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647–2654. DOI:10.1185/030079907X233395
- Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, et al. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–673.
- Kaplan WA, Ritz LS, Vitello M, et al. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy. 2012;106(3):211–224.
- Department of Health. The Pharmaceutical Price Regulation Scheme, 2009 http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_098498.pdf (Accessed Nov. 2023)
- Kanavos P. Overview of pharmaceutical pricing and reimbursement regulation in Europe. Japanese J Clin Pharmacol Ther. 2013;21(10):819–898.
- Department of health. 2014 PPRS: heads of Agreement for the 2014 Pharmaceutical Price Regulation Scheme. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/255252/pprs_heads_of_agreement_2014.pdf (Accessed Dec. 2022)
- Wentworth S. The low-down on the UK’s new pricing scheme. The Pharma Letter. 2019. Available from: https://www.thepharmaletter.com/article/the-low-down-on-the-uk-s-new-pricing-scheme
- Lomas JRS. Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment. Value Health. 2019;22(8):898e905.
- Hinterhuber A. Customer value-based pricing strategies: why companies resist. J Bus Strategy. 2008;29(4):41–50.
- Jommi C, Armeni P, Costa F, et al. Implementation of Value-based Pricing for Medicines. Clin Ther. 2020;42(1):15–24. DOI:10.1016/j.clinthera.2019.11.006
- Porter M. What is value in health care? N Engl J Med. 2010 Dec 23;363(26):2477–2481. DOI:10.1056/NEJMp1011024
- Garner S, Rintoul A, Hill SR. Value-Based Pricing: l’Enfant Terrible? Pharmacoeconomics. 2018;36(1):5–6.
- Moon S, Mariat S, Kamae I, et al. Defining the concept of fair pricing of medicine. BMJ. 2020;368:14726. DOI:10.11.1136/bmj14726
- CreativCeutical. New pricing models for generic medicines to ensure long-term healthy competitiveness in Europe. Reference: 21-MFE01GNR; 2022. New-pricing-models-for-generic-medicines.pdf
- WHO. Pharmaceutical pricing and reimbursement systems in Eastern Europe and Central Asia. Denmark: WHO Regional Office for Europe; 2020. Available from: https://www.euro.who.int/__data/assets/pdf_file/0007/455938/Pharmaceutical-pricing-eng.pdf
- Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plann. 2013;28(7):692–704. DOI:10.1093/heapol/czs108
- ECDirective 2004/109/EC of the European Parliament and of the Council of 15 December 2004 on the harmonisation of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market and amending Directive 2001/34/EC OJ L. Official Journal of the European Union. 2004 31 Dec;390:38–57.
- WHO. Medicines reimbursement policies in Europe. Copenhagen: Regional Office for Europe; 2018.
- WHO. Promoting Rational Use of Medicines: core Components. Available from: http://apps.who.int/medicinedocs/en/d/Jh3011e/2.html (Accessed Nov. 2022)
- WHO Policy perspectives on Medicines: the selection of essential medicines. Available from: http://whqlibdoc.who.int/hq/2002/WHO_EDM_2002.2.pdf (Accessed Nov. 2022)
- Glaeske G. Quality control of drug prescriptions by positive lists–the European Formulary. Int J Clin Pharmacol Ther. 1994;32(8):403–408.
- Kochen MM, Sandholzer H, Himmel W. Attitudes of primary care physicians towards the use of a drug formulary–preliminary results of a study in Germany. Int J Clin Pharmacol Ther. 1994;32(8):400–402.
- Welch WP. Giving physicians incentives to contain costs under Medicaid. Health Care Financ. 1990;12(2):103–112.
- Mossialos E, Walley T, Rudisill C. Provider incentives and prescribing behaviour in Europe. Expert Rev Pharmacoecon Outcomes Res. 2005;5(1):81–93.
- McCartney M. Prescribing incentives feel grubby because they are. BMJ. 2017;357:j2695. DOI:10.1136/bmj.j2695
- IGES institute. Reimbursement of Pharmaceuticals in Germany 2020-2021. An IGES Group company 2021. https://www.iges.com/e15094/e15095/e15096/e17469/IGES_Reimbursement_Pharmaceuticals_Germany_2020_2021_WEB_ger.pdf
- Wenzl M, Paris V Pharmaceutical reimbursement and pricing in Germany. OECD, 2018. Available from: https://www.oecd.org/els/health-systems/Pharmaceutical-Reimbursement-and-Pricing-in-Germany.pdf (Accessed Nov. 2022)
- Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Health Plann Manage. 2005;20(4):291–306.
- Vogler S, Martikainen J. Pharmaceutical Pricing in Europe. In: Book: pharmaceutical Prices in the 21st Century.Switzerland:Springer International Publishing; 2015. DOI:10.1007/978-3-319-12169-7_19
- Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. South Med Review. 2012;5(1):38–46. DOI:10.2174/1876824520130426001
- Vogler S, Paris V, Ferrario A, et al. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Appl Health Econ Health Policy. 2015;15(3):307–321. DOI:10.1007/s40258-016-0300-z
- Ferrario A, Araja D, Bochenek T, et al. The Implementation of Managed Entry Agreements in Central and Eastern Europe Findings and Implications. Pharmacoeconomics. 2017;35(12):1271–1285.
- Ferrario A, Kanavos PManaged entry agreements for pharmaceuticals: the European experienceThe London School of Economics and Political Sciences2013https://eprints.lse.ac.uk/50513
- Fens T, van Puijenbroek E, Postma ME. Safety, and Economics of Innovative Medicines: the Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy. Front Med Technol. 2021;3:629750.
- Rotar A, Preda A, Lobova O, et al. Rationalizing the use of pharmaceutical products: the role of managed entry agreements in central and Eastern European countries. Health Policy. 2018:122(3);230–236. DOI:10.1016/j.healthpol.2018.01.006
- Garrison L, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–719.
- Andersson E, Svensson J, Persson U, et al. Risk sharing in managed entry agreements-A review of the Swedish experience. Health Policy. 2020;124(4):404–410.
- Kolasa K, Kowalczyk M. Does cost sharing do more harm or more good? - a systematic literature review. BMC Public Health. 2016;16:992.
- EU. Regulation (EU) 2021/2282 on health technology assessment. Available from: https://health.ec.europa.eu/health-technology-assessment/regulation-health-technology-assessment_en (Accessed Nov. 2022)
- EUNetHTA. Available from: https://www.eunethta.eu/about-eunethta/history-of-eunethta/ (Accessed Nov. 2022)
- Christofides S, et al. The European Network for Health Technology Assessment — EUnetHTA. In: Magjarevic R, and Nagel J (editors) World Congress on Medical Physics and Biomedical Engineering 2006. IFMBE Proceedings, 2007; 14. Springer, Berlin, Heidelberg. DOI:10.1007/978-3-540-36841-0_942
- Drummond M, Jönsson B, Rutten F, et al. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2011;12(3):263–271. DOI:10.1007/s10198-010-0274-y
- Core Model License. https://www.eunethta.eu/wp-content/uploads/2018/01/HTACoreModel_Licence_12Jan2016_0.pdf (Accessed Jan 2023)
- Vogler S, Vitry A, Z-U-D B. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47.
- Jönsson B, Hofmarcher T, Lindgren P, et al. Comparator report on patient access to cancer medicines in Europe revisited. IHE Rep. 2016;4:228.
- Kamusheva M, Turcu-Stiolica A, Gierczynski J, et al. Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries-The Case of Bulgaria, Romania, and Poland. Front Public Health. 2021;9. DOI:10.3389/fpubh.2021.729847
- Perehudoff SK, Alexandrov NV, Hogerzeil HV. Access to essential medicines in 195 countries: a human rights approach to sustainable development. Glob Public Health. 2019;14(3):431–444.
- Mahmić-Kaknjo M, Jeličić-Kadić A, Utrobičić A, et al. Essential medicines availability is still suboptimal in many countries: a scoping review. J Clin Epidemiol. Internet 2018;98: 41. DOI:10.1016/j.jclinepi.2018.02.006
- WHO Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen; 2015.
- Seitaridou Y, Tsekov I, Kamusheva M, et al. Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Rev Pharmacoecon Outcomes Res. 2021;22(2):241–246.
- Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527–540.
- Pisana A, Wettermark B, Kurdi A, et al. Challenges and opportunities with routinely collected data on the utilization of cancer medicines. perspectives from health authority personnel across 18 European Countries. Front Pharmacol. 2022;13:873556.
- Thomson S, Mossialos E. Influencing demand for drugs through cost sharing. In: Mossialos E, Mrazek M, and Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Oxford University Press for the European Health Observatory; 2004. p. 227–245.
- Luiza V, Chaves L, Silva R, et al. Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines. Cochrane Database Syst Rev. 2015;5. CD007017. DOI:10.1002/14651858.CD007017.pub2
- Ito Y, Hara K, Yoo BK, et al. Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs. BMC Health Serv Res. 2019;19(1):780. DOI:10.1186/s12913-019-4598-8
- Vogler S, Schneider P, Dedet G, et al. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. Int J Equity Health. 2019;18(1):89. DOI:10.1186/s12939-019-0990-6
- Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and health status in vulnerable populations: a systematic review of the evidence. Int J Health Ser. 2004;34(1):101–122.
- Uyl-de Groot C, Heine R, Krol M, et al. Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe. Cancers (Basel). 2020;12(8):2313.
- Perehudoff K. Universal access to essential medicines as part of the right to health: a cross-national comparison of national laws, medicines policies, and health system indicators. Glob Health Action. 2020:13(1):1699342. DOI:10.1080/16549716.2019.1699342
- EFPIA Patients W.A.I.T. Indicator 2021 Survey. Available from: waiting to access innovative therapy. https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf (Accessed Nov. 2022)
- Kamusheva M, Dimitrova M, Tachkov K, et al. Pharmacotherapeutic patterns and patients’ access to pharmacotherapy for some rare diseases in Bulgaria – a pilot comparative study.Front. Pharmacol. 2021;12:695181.
- Tsekov I, Dimitrova M, Voynikov Y. Role of the EMA specific marketing authorization procedures for early access on the time to patient access in Bulgaria. Pharmacia. 2021;68(2):421–425.
- The Access To Medicine Foundation (Dec 21 2021). The Access to Medicine Index 2021. (Accessed: Dec. 2022)
- Access to medicines foundation. Access to medicines index, 2022. Available from: https://accesstomedicinefoundation.org/medialibrary/2022_access-to-medicine-index-1669982501.pdf (Accessed Dec. 2022)
- Niens LM, Brouwer WB. Measuring the affordability of medicines: importance and challenges. Health Policy. 2013;112:45–52. DOI:10.1016/j.healthpol.2013.05.018
- World health organization. Health action international. Measuring medicines prices. Availability, affordability and price component. Second ed. Geneva: WHO; 2008.
- Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–249.
- Wagstaff A, van Doorslaer E. Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993-1998. Health Econ. 2003Nov;12(11):921–34. DOI:10.1002/hec.776
- Wagstaff A, van Doorslaer E. Catastrophe and impoverishment in paying for health care: with application to Vietnam. 1993-1998. Health Econ. 2003;12(11):&921–34.
- Quintal C, Lopes J Catastrophic Expenditure on Medicines: an Analysis Based on the Portuguese Household Budget Survey 2015/2016. J EU Bus Res. 2021 ID: 935298. DOI:10.5171/2021.935298
- Selvaraj S, Farooqui HH, Karan A. Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994–2014. BMJ Open. 2018;8:e018020.